| Description | Imiquimod hydrochloride (R 837 hydrochloride) is a selective toll-like receptor 7 (TLR7) agonist and immune response modulator with antiviral and antitumor activity.Imiquimod hydrochloride has been used in studies of pemphigus foliaceus, skin cancer, and psoriasis. |
| In vivo | Imiquimod hydrochloride 通过诱导、合成和释放细胞因子来刺激先天免疫反应，包括干扰素-α (IFN-α)、白细胞介素 (IL)-6 和肿瘤坏死因子 (TNF)-α[1]。 |
| Synonyms | R837 hydrochloride, R-837 hydrochloride, Imiquimod HCl, R 837 hydrochloride |
| molecular weight | 276.77 |
| Molecular formula | C14H17ClN4 |
| CAS | 99011-78-6 |
| Storage | Powder: -20°C for 3 years | In solvent: -80°C for 1 year |
| Solubility | Methanol: 15 mg/mL (54.20 mM), Sonication is recommended. DMSO: 5 mg/mL (18.07 mM), Sonication and heating are recommended. Ethanol: 1 mg/mL (3.61 mM), Sonication is recommended. H2O: 2 mg/ml (7.23 mM), Sonication is recommended. |
| References | 1. Athina Angelopoulou, et al. Imiquimod - A toll like receptor 7 agonist - Is an ideal option for management of COVID 19. Environ Res. 2020 Sep; 188: 109858. 2. Yuji Kan, et al. Imiquimod suppresses propagation of herpes simplex virus 1 by upregulation of cystatin A via the adenosine receptor A1 pathway. J Virol. 2012 Oct;86(19):10338-46. 3. Aditya K Gupta, et al. Imiquimod: a review. J Cutan Med Surg. Nov-Dec 2002;6(6):554-60. 4. Michael P Schön, et al. The small antitumoral immune response modifier imiquimod interacts with adenosine receptor signaling in a TLR7- and TLR8-independent fashion. J Invest Dermatol. 2006 Jun;126(6):1338-47. |